Royal Bank of Canada’s Alterity Therapeutics ATHE Stock Holding History

Royal Bank of Canada’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5	Closed	–	–	6380
2016 Q2	$0	Hold	5	–	–	﹤0.01%	6352
2016 Q1	$0	Hold	5	–	–	﹤0.01%	6334
2015 Q4	$0	Hold	5	–	–	﹤0.01%	6619
2015 Q3	$0	Hold	5	–	–	﹤0.01%	6622
2015 Q2	$0	Hold	5	–	–	﹤0.01%	6567
2015 Q1	$0	Hold	5	–	–	﹤0.01%	6114
2014 Q4	$0	Hold	5	–	–	﹤0.01%	6153
2014 Q3	$1K	Buy	+5	New	+$669	﹤0.01%	5851

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $92.2M AUM 19.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada's ATHE Position: Q3 2016 in Review

Royal Bank of Canada sold out of Alterity Therapeutics (ATHE) in Q3 2016, closing a stake of 5 shares.

Royal Bank of Canada first reported a position in ATHE in Q3 2014 and held it in 8 quarters. The position peaked at $1K in Q3 2014. 16 funds tracked by Wall St. Rank hold ATHE as of Q3 2016.

Royal Bank of Canada reported no remaining Alterity Therapeutics position as of Q3 2016 after selling out during the quarter.
Royal Bank of Canada sold 5 Alterity Therapeutics shares in Q3 2016.
Royal Bank of Canada first reported a position in Alterity Therapeutics in Q3 2014 and held it in 8 quarters.
Royal Bank of Canada's Alterity Therapeutics position peaked at $1K in Q3 2014.
16 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2016.

Based on Royal Bank of Canada's 13F filing for Q3 2016, filed 14 Nov 2016.